Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized31P measurements of response to treatment
Open Access
- 1 November 1998
- journal article
- review article
- Published by Wiley in NMR in Biomedicine
- Vol. 11 (7) , 314-340
- https://doi.org/10.1002/(sici)1099-1492(1998110)11:7<314::aid-nbm522>3.0.co;2-z
Abstract
A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2–4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri‐phosphate (TNTP) (p = 0.02) over 3 (±1) weeks were significantly associated with response, as were the levels of PME (p < 0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (±1). PME at week 3 (±1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25%, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33%, with the reproducibility being better in patients measured on different days (difference in TP was −6%) compared with those measured on the same day (difference in TP was −29%). © 1998 John Wiley & Sons, Ltd.Keywords
This publication has 71 references indexed in Scilit:
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studiesPublished by Elsevier ,1996
- In vivo and in vitro studies of cyclophosphamide chemotherapy in a mouse mammary carcinoma by 31P NMR spectroscopyNMR in Biomedicine, 1995
- 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non‐involved breast tissueNMR in Biomedicine, 1994
- Primary medical (neo-adjuvant) chemotherapy for operable breast cancerEuropean Journal Of Cancer, 1993
- Phospholipid metabolites, prognosis and proliferation in human breast carcinomaNMR in Biomedicine, 1993
- Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinomaBreast Cancer Research and Treatment, 1991
- NMR studies of the lipid metabolism of T47D human breast cancer spheroidsFEBS Letters, 1990
- The Risk of Breast Cancer after Estrogen and Estrogen–Progestin ReplacementNew England Journal of Medicine, 1989
- BIOCHEMICAL INVESTIGATION OF HUMAN TUMOURS IN VIVO WITH PHOSPHORUS-31 MAGNETIC RESONANCE SPECTROSCOPYThe Lancet, 1986
- Regulation of phosphatidylcholine biosynthesis by mitogenic growth factorsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1984